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Background: Participant reports of medical histories, adverse events (AE) and non-study drugs are integral to
evaluating harm in clinical research. However, interpreting or synthesizing results is complicated if studies use
different methods for ascertaining and assessing these data. To explore how these data are obtained in malaria
drug studies, a descriptive online survey of clinical researchers was conducted during 2012 and 2013.
Methods: The survey was advertised through e-mails, collaborators and at conferences. Questions aimed to capture
the detail, rationale and application of methods used to obtain relevant data within various study designs and
populations. Closed responses were analysed using proportions, open responses through identifying repeating
ideas and underlying concepts.
Results: Of fifty-two respondents from 25 counties, 87% worked at an investigational site and 75% reported about
an interventional study. Studies employed a range of methods to elicit, assess and record participant-reported AEs
and related data. Questioning about AEs in 31% of interventional studies was a combination of general (open
questions about health) and structured (reference to specific health-related items), 26% used structured only and
18% general only. No observational studies used general questioning alone. A minority incorporated pictorial tools.
Rationales for the questioning approach included: standardization of assessment or data capture, specificity or
comprehensiveness of data sought, avoidance of suggestion, feasibility, and understanding participants’
perceptions. Most respondents considered the approach they reported was optimal, though several reconsidered
this. Four AE grading, and three causality assessment approaches were reported. Combining general and structured
questions about non-study drug use were considered useful for revealing and identifying specific medicines, while
pictures could enhance reports, particularly in areas of low literacy.
Conclusions: It is critical to evaluate the safety of anti-malarial drugs being deployed in large, diverse populations.
Many studies would be suitable for contributing to a larger body of evidence for answering questions on harm.
However this survey showed that various methods are used to obtain relevant data, which could influence study
results. As the best practices for obtaining such data are unclear, anti-malarial clinical researchers should work
towards consensus about the selection and/or design of optimal methods.
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When investigating drug effects, study results are
influenced by the methods used to collect, assess, record
and report outcomes. Studies using different methods
can be difficult to evaluate within a body of evidence, so
it is beneficial to harmonize conduct [1]. There has been
significant harmonization of methods relating to efficacy
outcomes. For malaria, this entails a World Health
Organization (WHO) protocol for therapeutic efficacy
evaluations and a categorization of treatment response
developed by the WorldWide Antimalarial Resistance
Network (WWARN) [2,3]. In general there has been less
attention to developing harmonized methods for eva-
luating safety (monitoring the presence or absence of
harm), reflecting its historical marginalization within
drug development [4-6]. Notable exceptions include case
definitions for adverse vaccine reactions, standard as-
sessment and reporting of adverse effects in rheumato-
logy, HIV and oncology, and instruments for determining
specific anticipated effects, for example, extrapyramidal
motor side effects of antipsychotics [7-11]. Little work
concerns the systematic detection of unanticipated
effects [12]. For malaria trials, WHO recommends that, to
ascertain the incidence of adverse events (AEs), partici-
pants be asked about symptoms that have emerged since
the previous follow-up visit by “direct questioning” [2].
The manner of ascertaining AEs from subjective
participant reports may be more problematic for harmo-
nization compared to those determined through tests or
examinations, as it is proposed the former are shaped by
memory, expectations, consideration of information re-
quired and willingness to report [13-15]. The interpre-
tation and comparison of AE data is further complicated
if studies use different methods for assessing severity
and relationship to study drug. Research shows that
questioning (elicitation) methods can play a role; when
asked about specific conditions or body systems as
opposed to general questions about health, participants
typically report more [16]. This suggests certain tech-
niques overcome particular barriers to reporting [13].
Some, therefore, recommend using questionnaires or
checklists of potential AEs due to their greater sensitivity
[17]. However, opinion is divided; despite evidence that
participants do not always report an AE when asked a
general question, some counsel against more detailed
questioning so as to prevent inducing a particular
response [9,18]. Others suggest that AEs detected by
detailed questioning are not as clinically meaningful as
those mentioned spontaneously and that general ques-
tioning provides a better evaluation of drug-placebo
difference [19,20]. That this initial stage of collecting AE
data has been largely excluded from efforts to harmonize
safety evaluation methods within some therapeutic areas
perhaps reflects these complexities and debates.Previous medical histories, non-study drugs (previous
or concomitant medication), and study drug adherence
data, all largely ascertained from participant reports, are
integral to assessing harm. Yet these are rarely included
in debate about the challenges of obtaining adverse
effect data, despite evidence that participants fail to
report some medications when asked [21]. As for AEs,
the questioning tool has been found to influence reports
[15,22].
It has been acknowledged that the above factors inhe-
rent in evaluating anti-malarial drug safety and tolerabi-
lity are challenging, and that there is a need for further
guidance [23]. To contribute to debate about these
concerns a survey was conducted about the methods
researchers use to obtain data for evaluating participant-
reported harms. A survey was chosen over a literature
review as the detail of how data are collected and
managed is insufficient in most publications [24]. A
survey could also prepare for subsequent collaborative
work within the anti-malarial research community, with
the aim of selecting or designing suitable harmonized
methods. This survey was conducted within the ACT
Consortium, a group of researchers conducting projects
relating to the wide-scale implementation of artemisinin-
based combination therapy [25]. Several projects con-
tribute safety outcome data to a register coordinated by
the Liverpool School of Tropical Medicine (in collabo-
ration with the Malaria in Pregnancy, MiP, Consortium),
which can produce individual study reports and pooled
analyses, and can also accept data from outside of the
ACT Consortium [26]. This will be a valuable resource for
understanding more about the harmful effects of anti-
malarials, particularly as drugs are being widely dis-
tributed within high-risk populations who could be quite
different to those studied within registration clinical trials.
Methods
Survey objective
The objective was to explore the methods used to detect,
assess and record participant-reported medical history,
AE, study drug adherence and non-study drug data in
anti-malarial clinical drug research.
Survey population and sampling
Those eligible were anyone involved in the elicitation
(by questioning) and recording of harms and related
data from participants in any malaria clinical drug study,
whether directly interacting with participants, or design-
ing questioning, assessment or data recording methods,
or taking responsibility for these tasks. There was no
sample size calculation due to the nature of this des-
criptive survey. Instead, the survey was as inclusive of
respondents as possible within the available budget
and timelines. Recruitment was active and passive.
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and potential eligible respondents identified from
PubMed, clinicaltrials.gov, the Pan-African Clinical
Trial Registry and the Initiative to Strengthen Health
Research Capacity in Africa’s database of African
Health Researchers [27-30]. The ACT Consortium,
MiP Consortium, WWARN, and Global Health Trials
publicized the survey through newsletters, webpages
or mailing lists, and it was advertised at several
conferences [25,26,31,32]. During recruitment it was
determined that sponsors may not always know the detail
required, though would be valuable in subsequent debates,
so they were not actively targeted further. Survey respon-
dents were asked to coordinate responses within project
teams unless members had differing experiences. Self-
selection ultimately determined who participated.
Survey conduct and analysis
The survey (Additional file 1) was developed in
SurveyGizmo® for completion online from August 2012 to
January 2013 [33]. Questions captured the detail, rationale
and application of methods used within various malaria
drug study designs and populations. Respondents were
also asked about important and feasible approaches over
and above what they had experienced. Examples of tools
(eg, case record forms) and recommended literature were
requested. It was too complex to ask about trial design,
such as length of participant follow-up, although these are
important aspects of assessing AEs that can also hinder
meta-analyses [24]. The questionnaire was piloted with
seven eligible respondents, establishing whether questionsFigure 1 Survey respondents by geographical region where respondewere understood as intended, and requesting suggestions
for improving content and conduct. That the survey was
considered acceptable and relevant contributed to face
and content validity. The survey was anticipated to take
20 minutes to complete. After recruitment, content was
downloaded into Microsoft Excel®. Closed question
responses are presented using proportions, and open
responses, through mapping underlying concepts and
repeating ideas identified [34].
Ethical considerations
The University of Cape Town’s Faculty of Health Sciences
Research Ethics Committee gave written approval for the
survey, and consent to take part was integral with its
completion. Access to responses was restricted to those in
the investigational team. Once analysis was complete the
survey was de-activated, removing links between e-mail
addresses and the website.
Results
Survey respondents and nature of studies described
There were 150 non-duplicate visits to the survey and
56 questionnaires sufficiently completed for inclusion.
Four were excluded as they concerned vaccine trials
which were not the focus of the survey. Of the
remaining 52, there was representation from 25 coun-
tries (Figure 1). Eighty-one per cent of respondents had
more than five years’ involvement in malaria clinical
research. Most (85%) worked at a study site; in addition
there were four representing sponsors/sponsor-investiga-
tors, four taking other coordinating roles and annt works most of the time (N = 52).
Figure 3 Questioning methods about health used to capture
AE data in interventional studies (N = 39, 2 = not known).
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dents were Principal Investigators (PIs), the remainder
being co-investigators/researchers (n = 10), study coordi-
nators (n = 7), or other/unknown (n = 2). Forty-three
(84%) took responsibility for selecting or developing the
methods used to collect participant-reported AE and/or
non-study drug data. The majority of clinical research
conducted by respondents was non-commercial (77%).
Respondents answered the survey with reference to
their most recent study, of which 39 (75%) were inter-
ventional, nine (17%) observational, the remainder
undefined. Studies employed a variety of staff to take a
medical history from participants or care-givers, inclu-
ding any change in health or use of treatments (Figure 2).
Sixty per cent of studies included children between one
and 17 years old; the median age in studies where
children were asked directly about their health was five
years, while for medication-use it was seven years. Forty
per cent (20/50) involved a translator in participant
conversations. The limited number (n = 5) and diversity
of the AE data collection tools submitted meant that
they could not be explored usefully. Hereafter N = 52
unless otherwise indicated (not all questions were rele-
vant for, or answered by, all respondents).
Questioning study participants about health to collect
AE data
A range of methods were applied to elicit participant-
reported AEs. Questioning in 12/39 (31%) of inter-
ventional studies was a combination of general (without
reference to particular conditions or body system) and
structured (with reference to particular conditions or
body system), while 10/39 (26%) were structured only
and 7/39 (18%) general only (Figure 3). All of the nine
observational studies described incorporated structured
questioning. General enquiries involved phraseologyFigure 2 Proportion of studies by staff member(s) who
question participants about health and drug use (N = 52).
“Other” most frequently referred to community health workers, field
workers and various trained members of the research team.about one of the following concepts (in descending
order of frequency by two or more respondents): general
enquiry about feeling (eg, “How have you [has your
child] been feeling?”), explicit enquiry about change in
health (eg, “Have you observed any change or new com-
plaint”), and enquiry with implied causality reference
(eg, “Did your child experience any serious side effect
from the drug”). One respondent used a phrase possibly
aimed at overcoming some impediments to reporting:
“Can you confide in us to give a sincere answer”. When
general phrases were mandatory for use in a study, all
respondents were confident the phrase was used as
prescribed (N = 12).
Structured enquiries involved numerous permutations
of symptoms (malaria-specific or not), body systems, and
expected adverse drug effects. When used, they were
mostly in reference to a prepared list (85%), either exactly
as prescribed, paraphrased or a combination. Other than
general and structured questioning, eight studies (N = 52,
14%), 5 of which were interventional (N = 39, 13%) incor-
porated other methods, including pictures and/or pictorial
diaries (eg, clinical presentations). Only one such tool was
referenced [35].
Key attributes valued in the rationale for method
choice were: standardization of AE assessment or data
capture, specificity or comprehensiveness of data sought,
avoidance of suggestion of a certain response, feasibility
and understanding participants’ perceptions about health
(Table 1). Other than more structured enquiries being
used to obtain comprehensive reports, there was overlap
in the use of different questioning methods to fulfil the
same rationales. Most respondents (35/47, 74%) said
the approach used in their last anti-malarial study to
elicit participant-reported AEs was the one they also
Table 1 Rationale for choice of questioning method about health and non-study drug treatment (28/52 respondents)
Example quotes
from respondents
Question method used in the study
General
enquiry
only
Structured
enquiry
only
General and
structured
enquiry
combination
Added pictures,
diary, charts,
collecting packets,
showing sample drugs
Standardization of assessments
or data capture (including historical
use of a method in the research group)
“A systematic approach based
on pharmacovigilance procedures
developed by our collaborators”
x x x
“We are used to that”
Specificity of data sought
(seeking information about particular
adverse events, malaria symptoms or drugs)
“We wanted to find out about
specific symptoms and adverse
effects”
x x x
“The named drug questions
targeted drugs of special interest”
Comprehensiveness of data sought
(participant guidance, report clarification,
overcoming barriers to reporting such as
poor recall or ability to name medicines)
“To provide a clear understanding
about what investigators are
looking for and to be sure they
capture all complaints from study
participants”
x x x
“To get more information which
may have been missed during
the initial interview”
Avoidance of suggestion “Keeping questions open and not
leading so that only events
significant to the patient are
reported”
x x
Feasibility “A simple screen [as the] main
focus of the study was not
safety/tolerability”
x x x
“Appears simple and not
complex”
Understand participants’ perceptions
about health
“[To] know if [symptoms] are
related to chronic disease or
traditional belief”
x x
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these reported that the original method worked or
was reliable, though no details were given on validity
or reliability assessments. Five respondents said, how-
ever, that the method depended on the needs and
circumstances of the study or participant population,
and 7 suggested an alternative to their originally
reported method; one moving from a combination of
general and structured questioning to only general
questioning (to reduce bias in reporting) and six by
proposing a more thorough strategy, incorporating
further types of questioning or tools. For the latter,
pictures, wall charts, and translations of instruments
into local languages were deemed potentially useful
for obtaining comprehensive data, and beneficial in
areas of low literacy. Seventy-seven per cent (36/50)
used the same method of assessing health at baseline
as for follow-up visits to detect AEs. Reasons for
using a different approach at baseline were to target
malaria symptoms and eligibility criteria, including
drug-related allergies.Assessing and recording AE data
A greater proportion of studies in which AEs were not
assessed for severity were observational (63 versus 11%
of interventional study reports). Of 20 respondents
describing an AE severity assessment method (19 inter-
ventional and one observational), 30% used a tool pub-
lished by the WHO, 20% by the Division of Microbiology
and Infectious Diseases, and 10% by the US National
Institute for Cancer [7,8,36]. One respondent commented
that the WHO tool does not work well for neutropenia
and other variables in their setting, citing Saathoff et al
[37]. The remaining 40% (all interventional), used the cat-
egories “mild, moderate, severe” (or synonyms), with vari-
ous definitions largely based on the concept of the AEs’
impact on daily living. Methods used to determine the re-
lationship between AEs and the study drug(s), included
the WHO-Uppsala Monitoring Centre causality tool,
Bradford Hill criteria, and a range of in-house categories
or those adopted from unknown sources [38,39]. Forty
per cent (19/47) said study participant AE reports were
entered verbatim into their database, either solely or with
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Standard terminologies were largely protocol-specific,
though three interventional study respondents cited use of
MedDRA® [40].
Non-study drug use
There were no obvious differences between obser-
vational and interventional studies in how non-study
drug data were elicited. The majority described general
questions (41/47, 87%), English terms being ‘medicine’,
‘medication’ or (less often) ‘drug’. There was no com-
mon practice for whether these phrases were required to
be used by study staff or not. Categories explicitly
referred to in general enquiries included: prescription-
only medicines (32/39, 82%), over-the-counter medicines
(27/39, 69%), traditional treatments (24/39, 62%), sup-
plements (11/38, 28%), and vaccinations (8/39, 21%).
Sixty per cent (28/47) of respondents used a structured
medication enquiry, largely in combination with the
general enquiry. About half of these incorporated a
study-specific tool specifying treatment class and/or
name. There were two reports of using pictures of either
a mosquito or drug packets to elicit non-study anti-
malarial drug use.
Structured enquires were deemed useful for revealing
specific medicines, particularly anti-malarials, and to
help name medicines mentioned in response to a
preliminary general enquiry. Pictures or diaries were
considered to enhance reports and were useful in areas
of low literacy (Table 1). Sixty-six per cent (27/41) of
respondents were comfortable the approach they used
was optimal. Those indicating it could be improved,
suggested augmenting a general enquiry with specific
mention (or pictures) of medicines such as anti-malarials
or drugs potentially interacting with the study drug. One
person recommended the content of such lists be deve-
loped from pre-study qualitative work in the target popu-
lation, though another described pictorial tools as “good
but logistically hard and…costly to develop”. A further
proposal was for all staff in contact with a participant to
enquire about non-study drug use. There was mention of
inherent limitations to questioning about non-study drug
intake, “To get medical attention [study participants] lie
they have not taken anything”, and one respondent sug-
gested assaying blood drug concentrations.
Study drug adherence data
Eighty per cent of reported studies (33/41) collected
study drug adherence data using combinations of dosing
being directly observed wholly or partially (n = 24), par-
ticipant recall (n = 14), pill counts (n = 7), dispensing
confirmation (n = 8), and pill diaries (n = 2). In 65% or
more of responses (N = 32), data were captured regar-
ding quantity of doses dispensed, doses observed,duration of total therapy, time of doses and whether the
participant vomited. About half of respondents reported
capturing the reason for non-adherence and whether the
study drug was taken with food (where applicable).
When patients vomited the usual practice was to repeat
the dose within a specified period and make a note in
the records. Definitions for adherence included taking
all doses appropriately, the proportion of participants
who took at least a specified percentage of study drug
(80 or 90%), and use of the categories adherent/probably
non-adherent/definitely non adherent. Seventy-nine per
cent said that adherence was described in the study
report.
Discussion
Exploring processes for evaluating harm in anti-malarial
drug research may offer insight into how study partici-
pants’ experiences become facts in databases. This was
the first investigation into the detail of methods used
within malaria clinical drug research to elicit, assess and
record participant-reported harms and associated data.
These are critical components of anti-malarial drug
safety evaluations, including systematic reviews and
meta-analyses, yet are not readily available in publi-
cations [41]. Fortunately, this situation is generally im-
proving [42]. An online survey was pragmatic and had
participation from 25 countries, representing over 50
studies.
Elicitation of AEs
The survey showed that various permutations of general
and structured questioning are used to elicit participant-
reported anti-malarial AEs, with a minority of studies
incorporating pictorial tools. The concern is that differ-
ences in questioning methods, even nuances between
general enquiries, influence data elicited [16,18]. The
few case record forms submitted validated the survey
findings that specific general enquiry phrases are obliga-
tory in some studies. While conversations are unlikely to
follow a script completely, a preliminary standard phrase
can orientate staff and participants to the intention of
questioning. Structured questioning for AEs with refe-
rence to predefined fields was frequently used to permit
standardized assessments and data capture, and obtain
comprehensive replies. While structured enquiries can
increase the number of AEs reported (hence burden on
the study team) they can also facilitate a tolerability
assessment, which is particularly important at a popula-
tion level [23]. The survey results reflect the literature
that children from five to seven years old can contribute
valuably in medical consultations. As young children
may be marginalized in conversations, however, it is pro-
posed that study staff are guided in managing triadic
communications [43].
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proach they used was optimal. However, the subtle
shifts observed between rationale for methods reported
in use and respondents’ perceptions of optimal ap-
proaches indicate reflection on appropriate methods, and
particularly the potential value of novel methods. In
other therapeutic areas, work is underway to harness
techniques used in developing validated patient-reported
outcome measures (PROs) for AEs, a trend being self-
report via the internet [44,45]. Many existing instru-
ments, however, restrict the development of items (i. e.
potential AEs) to those side-effects already associated
with a drug by patients and/or experts, and generate
summed scores rather than individual AE reports [46].
This may not allow for adequate detection of unex-
pected AEs or facilitate a traditional safety evaluation
through incidence measures. Nevertheless, finding ways
to better represent a participant’s experience of an AE
is important. For malaria it makes sense to pursue
methods suitable for areas of lower literacy, including
pictures, mobile phones, or innovative methods being
explored in other areas of health care communication,
such as when patients indicate health problems on
body outlines kept at home for later discussion at the
clinic [35,47].
The survey results did not substantiate whether
variation in AE enquiry methodology is a factor of study
design. This issue should be debated; for instance,
whether a more sensitive enquiry is used to detect AEs
in earlier phase trials, compared to later phase studies
where a drug has a better understood safety profile. The
caveat, however, is uncertainty about which questioning
method(s) produce valid data and whether there should
be consistency throughout study visits; while it is impor-
tant to avoid leading patients to a particular response,
it may also be inappropriate to use a less sensitive
measure to detect change in health post-intervention
than one used to determine a baseline. There should be
further methodological research to investigate these
concerns, including qualitative work in both participants
and staff about understanding of terminology and mea-
ningful outcomes in malaria-endemic populations. The
ACT Consortium plans to contribute through a Cochrane
review of research comparing adverse effect elicitation
methods [48]. Available data could potentially be distilled
to relevant concepts for local adaptation according to
the study design and population.
Grading severity of AEs
A variety of AE severity/toxicity grading tools and
methods for determining relationship with study drug
were reported. Researchers in other therapeutic areas
regularly debate the development of disease-specific
toxicity criteria for end points important to healthpractitioners and patients [9]. Should malaria researchers
do the same, such criteria should be based on locally
relevant reference ranges for laboratory parameters [49].
Staedke et al observed variability between sites in
assessing AEs for severity and causality when using
standard grading scales, reflecting differing value judge-
ments of staff and participants [23]. There is a need then
to think carefully about terminology and application of
criteria so that there is consistent interpretation [50].
Similarly, because of the plethora of causality assessment
criteria used in clinical research, there have been recom-
mendations of simpler categories (eg, related/not-related;
reasonable possibility/no possibility of attribution), with
more emphasis on determining causality by statistical
methods where possible [18,50].
Eliciting and recording study and non-study drug data
Survey respondents considered combining structured
and general questions about non-study drug use useful
for revealing and identifying specific medicines. Pictures,
diaries and samples etc, were seen to help with recall
and participant understanding of what to report, parti-
cularly pertinent for areas of low literacy. The cost of
formative work for development of such tools may be
prohibitive for individual study teams, but could be shared
with other groups recruiting from a similar patient popu-
lation (even if studying different therapeutic areas). Often
daily anti-malarial doses can be fully observed. However,
when required (e g, for twice daily dosing of artemether-
lumefantrine), there were various methods reported as
being used for measuring adherence, whether indirect and
objective (pill counts and dispensing information) or indi-
rect and subjective (diaries and recall). Combining recall
questionnaires or pill diaries with an electronic pillbox
and count may provide the most accurate information,
though in areas of low literacy or limited study budget a
recall questionnaire with pill count may be more realistic
(WWARN, personal communication, 2012). More work is
needed to define adherence for the variety of drugs or
combinations used in malaria to inform meta- or pooled
data analyses.
Limitations
Surveys inherently have constraints in terms of their
reach, respondents’ understanding of questions and their
ability or willingness to give comprehensive answers. It
is assumed that responses reflect the methods used in
practice. However, it would have strengthened the study if
other field staff were included to know whether their
responses differed from those of the PIs, co-investigators,
study coordinators and researchers who took part. The
survey results do not represent all anti-malarial drug
clinical research studies and it was not possible to detect
differences in methodologies between study designs or
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overcome in future debates. In particular, more represen-
tation from sponsor organizations and regulatory autho-
rities will be key.Conclusion
Many anti-malarial drug studies would be suitable for
contributing to a larger body of evidence for answering
questions on harm, regardless of design or whether
safety was the primary objective [51,52]. Meta-analysing
and pooling data can increase the power to generate
new signals, and clarify the incidence and possibly
drivers of known harms. Applying these tools is increa-
singly urgent as large populations, some who may have
multiple co-morbidities or be taking concomitant medi-
cations, are exposed to anti-malarial drugs. Should anti-
malarials be distributed in asymptomatic or malaria
negative populations it is particularly important to evalu-
ate benefits versus risk [53]. Studies evaluating strategies
such as intermittent presumptive treatment, screening
and treatment, and mass drug administrations should
assess safety, including the less severe adverse effects as
tolerability can impact on community acceptance of, and
individual adherence to medicines [54]. In order to
synthesize study results effectively researchers need to
move towards harmonized methods for obtaining safety
data. As there are many unanswered questions about
the best practices for eliciting, assessing and recor-
ding such data, priority areas for further work should
be established through dialogue within the anti-
malarial clinical research community. This could include
1) nesting methodological research within studies to find
optimal approaches or tools for questioning participants
to obtain AEs and related data, 2) deciding whether to
adopt an existing toxicity grading scheme from another
therapeutic area or develop one for malaria endemic popu-
lations, or 3) developing guidance on use of a common
causality assessment tool. User-friendly open access data-
bases suitable for a range of study designs could also be
developed collaboratively to help researchers manage
their data efficiently [55]. Where appropriate these
should incorporate harmonized fields and terminologies
so that they may be used more widely in the non-
commercial sector. The ACT Consortium plans to con-
tribute by facilitating a Delphi process; a summary of
the available literature will be presented to interested
malaria clinical researchers who will then work towards
consensus about the appropriate design of relevant and
feasible methods to detect these important data. This
work could also catalyze much needed progress in the
detection and investigation of harms in other thera-
peutic areas, generally improving the ability to compare
or synthesize studies [56].Additional file
Additional file 1: Survey questionnaire. Content of online survey.
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